Ketamine therapy is not the right treatment for every person who has struggled with depression, PTSD, anxiety, or chronic pain — and we think patients deserve to know that clearly, before they ever pick up a phone or fill out a contact form. Candidacy is determined through a thorough evaluation that looks at your full clinical history, not a checklist completed in a waiting room. At Mend The Mind in Livingston, Montana, that evaluation is where every treatment relationship begins, and it is designed to give you an accurate answer rather than a default yes.
The Core Clinical Question
The central question in a ketamine therapy candidacy evaluation is not simply whether you have a diagnosis that ketamine research has addressed. It is whether your treatment history, your medical profile, your support circumstances, and your clinical presentation together suggest that IV ketamine therapy is the appropriate next step for your specific situation.
For most patients who ultimately begin ketamine therapy at Mend The Mind, the path to our clinic runs through a history of inadequate response to conventional treatment. This pattern — clinically described as treatment resistance — is the most common and most clearly supported indication for ketamine therapy. Research from the National Institutes of Health demonstrates that ketamine produces rapid antidepressant effects specifically in patients who have not responded to other medications, identifying treatment resistance as a key factor distinguishing candidates who are most likely to benefit from those for whom earlier-line options have not yet been fully explored.
For depression specifically, treatment resistance is generally understood as inadequate response to at least two antidepressant medications — SSRIs (selective serotonin reuptake inhibitors) or SNRIs (serotonin-norepinephrine reuptake inhibitors), for example — taken at therapeutic doses for a sufficient duration. Research on SSRIs supported by the National Institutes of Health documents both their efficacy as first-line treatments and their limitations, establishing the clinical context within which ketamine becomes relevant: not as a replacement for medications that work, but as a distinct option for patients they have not adequately helped.
Treatment resistance is a meaningful threshold, not an arbitrary gatekeeping requirement. It exists because ketamine therapy involves real clinical considerations — monitoring requirements, dissociative effects, cost, and scheduling demands — that make it appropriate as a considered next step rather than a first resort.
Conditions We Evaluate For
At Mend The Mind, we evaluate adults for IV ketamine therapy and ketamine troches across the following conditions: treatment-resistant depression, anxiety, PTSD, OCD, bipolar disorder, suicidal ideation, and chronic pain conditions including fibromyalgia, neuropathic pain, and restless legs syndrome. Having one of these conditions does not automatically make you a candidate — it means your situation is within the scope of what we evaluate.
Each condition has its own evidence profile for ketamine therapy, and we discuss that honestly during your evaluation. Depression and suicidal ideation have the most robust research support for rapid response to IV ketamine. PTSD has a growing and compelling evidence base. OCD and anxiety show promising but more variable findings in the research. Chronic pain conditions may benefit from ketamine’s effects on NMDA receptors — the proteins in the brain and nervous system that play a central role in central sensitization, the process by which the nervous system amplifies pain signals — though pain protocols differ from psychiatric protocols in structure and duration.
Where evidence is preliminary or limited for a specific condition or use case, we say so. Our goal is not to sell you a treatment — it is to help you make an informed decision about whether this treatment is worth pursuing given your specific history and goals.
What We Look for in Your Treatment History
The evaluation at Mend The Mind involves a detailed review of your prior treatment history. This includes which medications you have tried, at what doses, for how long, and what your response was. It includes any therapy or other interventions you have completed and how you responded. It includes your current medications and any conditions — psychiatric or medical — that are relevant to how ketamine behaves in your system.
Certain medications interact with ketamine and may need adjustment before treatment begins. Some psychiatric presentations require careful evaluation before ketamine therapy is considered — including active substance use disorders, unstable cardiac conditions, a history of psychosis, or uncontrolled high blood pressure. These are not automatic disqualifiers in every case, but they are factors that require thorough clinical review rather than being glossed over.
We also review whether you have tried prior treatments at truly adequate doses and durations. Some patients arrive believing they have treatment-resistant depression when, in fact, they have not yet completed a full therapeutic trial of a medication that might help them. That distinction matters, and we are straightforward about it when it applies. Ketamine therapy is most appropriately positioned as a next step when prior options have genuinely been given a fair trial — not as a shortcut past treatments that might still be relevant.
Practical Candidacy Factors
Beyond clinical history, several practical factors bear on whether ketamine therapy is viable and appropriate for your situation.
Transportation is one. You cannot drive yourself to or from IV ketamine infusions — a reliable, safe ride is required for every session without exception. Our standard initial protocol involves six infusions over two to three weeks, which means this is not a one-time logistical arrangement but a sustained commitment. If transportation is a genuine barrier, discuss it during your consultation; we can talk through options including our at-home troche maintenance path for patients who have established response through IV treatment.
A support system, while not a strict requirement, meaningfully influences outcomes and safety. Patients who have family, friends, or a therapist helping them process and integrate what emerges during and after treatment tend to benefit more fully from the neuroplastic window that follows each infusion. This does not mean you cannot pursue ketamine therapy if you live alone — it means we factor your support circumstances into our recommendations.
Realistic expectations are another candidacy consideration we take seriously. Ketamine therapy may produce rapid and meaningful improvement for patients who meet criteria. Individual results vary, and some patients do not respond to ketamine or respond only partially. We do not represent it as a guaranteed outcome, and patients who arrive with that expectation deserve a frank conversation before treatment begins.
Who Is Not a Good Candidate
It is as important to be clear about who is not a good candidate as it is to describe who is. Patients who have active, untreated substance use disorders are generally not appropriate candidates for ketamine therapy due to the risks of misuse and the complexity of clinical management. Patients with a history of psychosis or certain personality disorders that affect how dissociative experiences are processed require particularly careful evaluation. Active suicidal crisis requiring immediate intervention is a situation that calls for emergency services, not an outpatient ketamine consultation — though IV ketamine has a documented role in reducing suicidal ideation as part of a comprehensive clinical plan once acute safety is established.
Patients who are medically unstable, who have uncontrolled blood pressure, or who have active cardiac conditions that make the hemodynamic effects of ketamine — the temporary increases in heart rate and blood pressure that the medication can produce — a significant safety risk also require careful evaluation. These conversations happen during your initial assessment, not after treatment has already started.
We would rather tell you clearly that ketamine therapy is not the right fit for your current situation than begin a treatment course that is unlikely to help or that carries avoidable risk. That directness is a feature of how we practice, not a limitation.
Addressing Scheduling as a Barrier
The most consistent practical barrier beyond cost that patients raise is schedule. Six infusions over two to three weeks, each requiring a ride to and from Livingston, is a real commitment — especially for patients traveling from surrounding communities across rural Montana. We do not minimize that.
For patients who respond to the initial IV series and are looking for a lower-intensity maintenance path, we offer ketamine troches — dissolvable lozenges prescribed for at-home use under our ongoing medical supervision. This option allows patients to maintain therapeutic benefits without requiring clinic attendance for every dose, which substantially reduces the ongoing scheduling burden. Whether troches are appropriate depends on your clinical response and circumstances, and it is a conversation we have with every patient who completes an initial series.
We schedule appointments Monday through Friday, 9 AM to 5 PM, by appointment only. If your work schedule or travel distance creates a constraint, raise it early — we factor real-life logistics into treatment planning from the start.
Addressing Cost as a Barrier
Pricing for IV ketamine therapy at Mend The Mind is discussed directly during your consultation. We do not publish it on our website because treatment plans are individualized, and a single figure would not accurately represent what your specific plan involves. We are an out-of-network provider. Every patient receives a detailed superbill through the Osmind care management platform following each session, which can be submitted to your insurance company for potential out-of-network reimbursement. Coverage outcomes vary significantly by plan, and we recommend contacting your insurer before your consultation to ask about your out-of-network benefits for ketamine therapy.
We are committed to making the financial side of treatment fully transparent before any commitment is made. If cost is a deciding factor in whether you pursue a consultation, contact us — we would rather have that conversation directly than have it be the undisclosed reason a patient who might have benefited from treatment does not pursue it.
Frequently Asked Questions
Do I need a referral from my psychiatrist or primary care provider to be evaluated?
No referral is required to schedule a consultation at Mend The Mind. Many patients come to us directly after researching their options or after exhausting what their current providers have been able to offer. If you have records from prior treatment providers, bringing them to your evaluation is helpful — your treatment history is central to the candidacy assessment.
I’ve only tried one antidepressant. Does that disqualify me?
Not necessarily, though the strongest clinical evidence for ketamine therapy applies to patients with documented treatment resistance — meaning inadequate response to at least two prior treatments at therapeutic doses. If you have only tried one medication, we may discuss whether additional first-line options are worth exploring before ketamine therapy. The evaluation is designed to give you an honest answer about where you are in that process.
I have a history of substance use. Can I still be evaluated?
A history of substance use does not automatically disqualify you. Active, untreated substance use disorder is a contraindication that requires careful clinical consideration, but patients in stable recovery are evaluated on a case-by-case basis. Be honest about your history during your consultation — it allows us to assess your situation accurately rather than making assumptions.
What happens if I go through the evaluation and I’m not a candidate?
We tell you directly, and we explain why. If IV ketamine therapy is not appropriate for your current situation, we discuss what that means for your options — whether that is returning to first-line treatments, pursuing evaluation with another type of provider, or reconsidering in the future if your circumstances change. A clear answer is more useful to you than an ambiguous one.
How long does the candidacy evaluation take?
The initial evaluation is a comprehensive appointment rather than a brief intake. We review your medical and psychiatric history, current medications, prior treatment trials, and treatment goals in detail. Plan for a thorough conversation — this is not a process we move through quickly, because the accuracy of the assessment depends on having a complete picture of your history.
Key Takeaways
- Candidacy for ketamine therapy is determined through a comprehensive evaluation of your treatment history, medical profile, practical circumstances, and clinical presentation — not by diagnosis alone.
- The most clearly supported indication for IV ketamine therapy is documented treatment resistance: inadequate response to at least two prior treatments at therapeutic doses for a sufficient duration.
- At Mend The Mind, we evaluate adults for ketamine therapy across ten conditions including depression, PTSD, anxiety, OCD, bipolar disorder, suicidal ideation, and chronic pain conditions — with honest discussion of the evidence base for each.
- Practical factors including transportation, support systems, and scheduling capacity are part of the candidacy conversation; ketamine troches are available as a maintenance option that reduces clinic visit frequency for patients who complete an initial IV series.
- Results vary by individual. Ketamine therapy is not appropriate for every patient, and we prioritize honest assessment over default acceptance into treatment.
Conclusion
Candidacy for ketamine therapy is a clinical determination — not a marketing category — and the evaluation process at Mend The Mind is designed to give you a real answer about whether this treatment is a reasonable fit for your situation. If it is, we build a plan grounded in your specific history and goals. If it is not, we tell you that clearly and discuss what your options are. Results vary by individual, and the process begins with a direct conversation. Call us at 406-350-4439, email mendthemindmt@gmail.com, or request a consultation through our website whenever you are ready to take that step.
References
National Institutes of Health. Antidepressant Efficacy in Treatment-Resistant Depression. https://pubmed.ncbi.nlm.nih.gov/23982301/
National Institutes of Health. Ketamine Side Effects. https://www.nih.gov/news-events/news-releases/side-effects-mild-brief-single-antidepressant-dose-intravenous-ketamine
National Institutes of Health. SSRIs. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy and all treatments discussed here should only be pursued under the supervision of a qualified, licensed healthcare provider who is familiar with your full medical and psychiatric history. Individual results vary, and Mend The Mind does not guarantee specific outcomes from any treatment. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.